Andrew Green Sells 44,001 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 44,001 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Artivion Stock Up 1.6%

AORT stock opened at $21.41 on Wednesday. The stock has a market capitalization of $1.04 billion, a P/E ratio of 89.23 and a beta of 1.26. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25. The firm has a 50-day moving average price of $28.41 and a 200-day moving average price of $36.62.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AORT. Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 target price on shares of Artivion in a report on Tuesday. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Needham & Company LLC dropped their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Citizens Jmp dropped their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Finally, LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.17.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA bought a new position in Artivion during the 1st quarter worth approximately $295,000. Bank of America Corp DE raised its holdings in Artivion by 0.8% during the 1st quarter. Bank of America Corp DE now owns 522,515 shares of the company’s stock worth $19,135,000 after purchasing an additional 3,980 shares during the last quarter. Amundi raised its holdings in Artivion by 7.5% during the 1st quarter. Amundi now owns 7,186 shares of the company’s stock worth $263,000 after purchasing an additional 501 shares during the last quarter. California State Teachers Retirement System raised its holdings in Artivion by 33.4% during the 1st quarter. California State Teachers Retirement System now owns 51,213 shares of the company’s stock worth $1,875,000 after purchasing an additional 12,825 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of Artivion by 73.1% during the 1st quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock worth $3,430,000 after buying an additional 39,553 shares during the period. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.